SBIR/STTR Research Award

Development of Pluripotent Amniotic Stem Cell Banks for Disease Modeling

Award identifier 76da16d6e98456a13dd398ebf310ca01a67f760e4e26eea179b2b8db602651c8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,305

Program and phase

SBIR · Phase I

Award year

2011

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TECHTOWN VENTURES,, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PA10-050
Topic code
NIGMS

Research abstract

DESCRIPTION (provided by applicant): Direct reprogramming of somatic cells with the transcription factors Oct4 (also called Pou5f1), Sox2, Klf4 and Myc1 yields induced Pluripotent Stem (iPS) cells with marked similarity to Embryonic Stem (ES) cells. When the source of the cells is patients affected by various disorders iPS cells promise to be excellent models to study the gradual pathogenesis of disease. However, there is recent evidence that iPS cells derived from adult tissues retain residual DNA methylation signatures characteristic of their somatic tissue of origin, which appears to restrict their differentiation potential. Human amniotic fluid (AF) cells have been used for prenatal diagnosis of chromosomal and Mendelian disorders for decades. Thereis a subpopulation of cells in AF that expresses the tyrosine kinase receptor c-Kit appear to have stem cell-like properties. Developmentally and functionally, they represent a class of stem cells with intermediate characteristics between embryonic and adult stem cells. Our hypotheses are that c-kit expressing AF cells can be reprogrammed using fewer exogenous proteins than necessary with adult cells and that the resulting iPS cells will have methylation patterns more similar to embryonic stem cells than toadult derived iPS cells. Such pluripotent stem cell lines would provide models with which to investigate the underlying mechanisms of a variety of genetic diseases, leading to new diagnostic and treatment modalities. Human amniotic fluid may provide a source of cells capable of generating more applicable disease-specific iPS cells. Our specific aims are: 1) characterize subpopulations of cells obtained from AF after cytogenetic diagnosis has confirmed the presence of genetic abnormalities; 2) determine minimal requirements for reprogramming AF cell subpopulations identified in Aim 1 to generate iPS cells. Our long-term goal is to develop banks of AF derived iPS cell lines representing different genetically related diseases. PUBLIC HEALTH RELEVANCE:We propose to create stem cell lines for the study of genetic diseases from amniotic fluid cells left over after diagnosis. Such stem cell lines would provide excellent models with which to investigate the underlying mechanisms of a variety of geneticdiseases, leading to new diagnostic and treatment modalities.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.